FIELD: medicine; chemistry; pharmaceutics.
SUBSTANCE: group of inventions relates to chemical-pharmaceutical industry and medicine. Disclosed is a pharmaceutical composition containing a derivative of favipiravir, namely a compound characterized by Formula I, its use and a medicinal agent based thereon. In formula I, X is an amino acid residue selected from a group comprising lysine, ornithine, histidine.
EFFECT: said pharmaceutical composition and medicinal agent have improved physicochemical, technological and pharmacological properties, as well as reduce the risk of increasing the level of hepatic transaminases during therapy, which is associated with toxic liver damage.
21 cl, 2 dwg, 1 tbl, 4 ex
Formula I
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING NOVEL DERIVATIVES OF FAVIPIRAVIR | 2023 |
|
RU2828875C1 |
| ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AN AMINO ACID, MEDICINAL PRODUCT CONTAINING SAID COMPOSITION, AND APPLICATION THEREOF FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS | 2021 |
|
RU2783282C1 |
| ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AMINO ACID, DRUG CONTAINING IT, AS WELL AS THEIR USE FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS | 2022 |
|
RU2814927C1 |
| ANTIVIRAL COMPOSITION | 2020 |
|
RU2751108C1 |
| ANTIVIRAL COMPOSITION | 2020 |
|
RU2740660C1 |
| ANTIVIRAL COMPOSITION | 2020 |
|
RU2740657C1 |
| ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AMINO ACID HYDRATE AND/OR ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2021 |
|
RU2789612C1 |
| ANTI-COVID-19 (SARS-COV-2) VIRAL PHARMACEUTICAL COMPOSITION | 2020 |
|
RU2731932C1 |
| ANTI-SARS-CoV-2-VIRAL PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 2020 |
|
RU2764444C1 |
| ANTI-RNA VIRAL, INCLUDING ANTI-CORONAVIRUS AGENT - SUBSTITUTED QUINOXALINE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS | 2020 |
|
RU2744429C1 |
